Xiaowei Chang
Direktor/Vorstandsmitglied bei AMBRX INC
Profil
Xiaowei Chang is currently the Director at Ambrx, Inc. and the Managing Director-Healthcare Investment at Hopu Investments Co. Ltd.
He previously served as an Independent Director at Ambrx Biopharma Cayman, Inc. from 2015 to 2023 and as a Senior Associate at China International Capital Corp.
Ltd.
(Private Equity) from 2011 to 2014.
Mr. Chang received his undergraduate and graduate degrees from Tsinghua University.
Aktive Positionen von Xiaowei Chang
Unternehmen | Position | Beginn |
---|---|---|
AMBRX INC | Direktor/Vorstandsmitglied | 01.06.2015 |
Hopu Investments Co. Ltd.
Hopu Investments Co. Ltd. Financial ConglomeratesFinance Hopu Investments Co. Ltd. functions as an investment holding Caymanian company. | Corporate Officer/Principal | 01.01.2014 |
Ehemalige bekannte Positionen von Xiaowei Chang
Unternehmen | Position | Ende |
---|---|---|
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Direktor/Vorstandsmitglied | 06.10.2023 |
China International Capital Corp. Ltd. (Private Equity) | Corporate Officer/Principal | 01.01.2014 |
Ausbildung von Xiaowei Chang
Tsinghua University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
China International Capital Corp. Ltd. (Private Equity) | Finance |
Hopu Investments Co. Ltd.
Hopu Investments Co. Ltd. Financial ConglomeratesFinance Hopu Investments Co. Ltd. functions as an investment holding Caymanian company. | Finance |